Veracyte (VCYT) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic vision and platform approach

• Focus on transforming global cancer care through advanced molecular diagnostics, broad genomic assays, and a platform approach that generates more data per test, driving clinical utility and adoption.

• Platform supports risk assessment, diagnosis, prognosis, treatment guidance, and monitoring across multiple cancer types, including breast, prostate, bladder, thyroid, urology, endocrinology, pulmonology, and women's health.

• Over 800,000 patients served and more than 600 supporting publications as of 2025.

Financial performance and growth outlook

• 2025 revenue expected at ~$516 million, with 17% testing revenue growth, led by Afirma and Decipher.

• Industry-leading profitability, achieving >25% Adjusted EBITDA in 2025 and targeting this margin in 2026 and beyond.

• 2026 revenue guidance of $570–$582 million, with 14–16% core testing revenue growth and 10–13% overall YOY growth.

• Nearly $400 million in cash and no debt, enabling both organic and inorganic growth opportunities.

Core product performance and market penetration

• Decipher is the leading prostate cancer test, with ~33% market penetration and over 300,000 patients tested; 15 consecutive quarters of >20% volume growth.

• Afirma has tested over 400,000 patients, ~38% market penetration, and 11% volume growth in 2025, aided by expanded reimbursement.

• Both tests are supported by extensive clinical evidence, guideline inclusion, and over 115 Decipher and 150 Afirma publications.